BIOMAT Database Logo BIOMAT Database Logo

Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. 2008

Yumi Mitsuya, and Vici Varghese, and Chunlin Wang, and Tommy F Liu, and Susan P Holmes, and Prerana Jayakumar, and Baback Gharizadeh, and Mostafa Ronaghi, and Daniel Klein, and W Jeffrey Fessel, and Robert W Shafer
Department of Medicine, Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA.

T215 revertant mutations such as T215C/D/E/S that evolve from the nucleoside reverse transcriptase (RT) inhibitor mutations T215Y/F have been found in about 3% of human immunodeficiency virus type 1 (HIV-1) isolates from newly diagnosed HIV-1-infected persons. We used a newly developed sequencing method-ultradeep pyrosequencing (UDPS; 454 Life Sciences)--to determine the frequency with which T215Y/F or other RT inhibitor resistance mutations could be detected as minority variants in samples from untreated persons that contain T215 revertants ("revertant" samples) compared with samples from untreated persons that lack such revertants ("control" samples). Among the 22 revertant and 29 control samples, UDPS detected a mean of 3.8 and 4.8 additional RT amino acid mutations, respectively. In 6 of 22 (27%) revertant samples and in 4 of 29 control samples (14%; P = 0.4), UDPS detected one or more RT inhibitor resistance mutations. T215Y or T215F was not detected in any of the revertant or control samples; however, 4 of 22 revertant samples had one or more T215 revertants that were detected by UDPS but not by direct PCR sequencing. The failure to detect viruses with T215Y/F in the 22 revertant samples in this study may result from the overwhelming replacement of transmitted T215Y variants by the more fit T215 revertants or from the primary transmission of a T215 revertant in a subset of persons with T215 revertants.

UI MeSH Term Description Entries
D003062 Codon A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE). Codon, Sense,Sense Codon,Codons,Codons, Sense,Sense Codons
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013489 Suppression, Genetic Mutation process that restores the wild-type PHENOTYPE in an organism possessing a mutationally altered GENOTYPE. The second "suppressor" mutation may be on a different gene, on the same gene but located at a distance from the site of the primary mutation, or in extrachromosomal genes (EXTRACHROMOSOMAL INHERITANCE). Suppressor Mutation,Genetic Suppression,Genetic Suppressions,Mutation, Suppressor,Mutations, Suppressor,Suppressions, Genetic,Suppressor Mutations
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017422 Sequence Analysis, DNA A multistage process that includes cloning, physical mapping, subcloning, determination of the DNA SEQUENCE, and information analysis. DNA Sequence Analysis,Sequence Determination, DNA,Analysis, DNA Sequence,DNA Sequence Determination,DNA Sequence Determinations,DNA Sequencing,Determination, DNA Sequence,Determinations, DNA Sequence,Sequence Determinations, DNA,Analyses, DNA Sequence,DNA Sequence Analyses,Sequence Analyses, DNA,Sequencing, DNA
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts
D019562 Viral Load The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression. Viral Burden,Virus Titer,Burden, Viral,Load, Viral,Titer, Virus

Related Publications

Yumi Mitsuya, and Vici Varghese, and Chunlin Wang, and Tommy F Liu, and Susan P Holmes, and Prerana Jayakumar, and Baback Gharizadeh, and Mostafa Ronaghi, and Daniel Klein, and W Jeffrey Fessel, and Robert W Shafer
Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.
May 1998, Journal of virology,
Yumi Mitsuya, and Vici Varghese, and Chunlin Wang, and Tommy F Liu, and Susan P Holmes, and Prerana Jayakumar, and Baback Gharizadeh, and Mostafa Ronaghi, and Daniel Klein, and W Jeffrey Fessel, and Robert W Shafer
Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.
August 2004, Journal of virology,
Yumi Mitsuya, and Vici Varghese, and Chunlin Wang, and Tommy F Liu, and Susan P Holmes, and Prerana Jayakumar, and Baback Gharizadeh, and Mostafa Ronaghi, and Daniel Klein, and W Jeffrey Fessel, and Robert W Shafer
Human Immunodeficiency Virus type 1 reverse transcriptase.
February 1996, Biological chemistry Hoppe-Seyler,
Yumi Mitsuya, and Vici Varghese, and Chunlin Wang, and Tommy F Liu, and Susan P Holmes, and Prerana Jayakumar, and Baback Gharizadeh, and Mostafa Ronaghi, and Daniel Klein, and W Jeffrey Fessel, and Robert W Shafer
Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
August 1999, The Journal of infectious diseases,
Yumi Mitsuya, and Vici Varghese, and Chunlin Wang, and Tommy F Liu, and Susan P Holmes, and Prerana Jayakumar, and Baback Gharizadeh, and Mostafa Ronaghi, and Daniel Klein, and W Jeffrey Fessel, and Robert W Shafer
Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.
October 1996, The Journal of infectious diseases,
Yumi Mitsuya, and Vici Varghese, and Chunlin Wang, and Tommy F Liu, and Susan P Holmes, and Prerana Jayakumar, and Baback Gharizadeh, and Mostafa Ronaghi, and Daniel Klein, and W Jeffrey Fessel, and Robert W Shafer
Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
May 1994, The Journal of general virology,
Yumi Mitsuya, and Vici Varghese, and Chunlin Wang, and Tommy F Liu, and Susan P Holmes, and Prerana Jayakumar, and Baback Gharizadeh, and Mostafa Ronaghi, and Daniel Klein, and W Jeffrey Fessel, and Robert W Shafer
Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase.
June 2000, Antimicrobial agents and chemotherapy,
Yumi Mitsuya, and Vici Varghese, and Chunlin Wang, and Tommy F Liu, and Susan P Holmes, and Prerana Jayakumar, and Baback Gharizadeh, and Mostafa Ronaghi, and Daniel Klein, and W Jeffrey Fessel, and Robert W Shafer
Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations.
June 2006, Biochemistry,
Yumi Mitsuya, and Vici Varghese, and Chunlin Wang, and Tommy F Liu, and Susan P Holmes, and Prerana Jayakumar, and Baback Gharizadeh, and Mostafa Ronaghi, and Daniel Klein, and W Jeffrey Fessel, and Robert W Shafer
Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.
November 2009, Antimicrobial agents and chemotherapy,
Yumi Mitsuya, and Vici Varghese, and Chunlin Wang, and Tommy F Liu, and Susan P Holmes, and Prerana Jayakumar, and Baback Gharizadeh, and Mostafa Ronaghi, and Daniel Klein, and W Jeffrey Fessel, and Robert W Shafer
Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility.
January 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Copied contents to your clipboard!